20

What is Claimed is:

solvate thereof, wherein

1. A compound of formula (I):

$$R^3Y$$
 R^2X
 R^1
 R^4
 R^4
 R^4
 R^4
 R^4
 R^4
 R^4
 R^4

or an enantiomer, diastereomer, or pharmaceutically acceptable salt, prodrug, or

Z is selected from O, S, N, OH, or Cl, with the provisos that when Z is O or S, R⁴¹ is

absent and when Z is OH or Cl, both R⁴¹ and R⁴² are absent and when Z is N,
then R⁴¹ is H.

X and Y are independently selected from O, OCO, S, SO, SO₂, CO, CO₂, NR¹⁰, NR¹¹CO, NR¹²CONR¹³, NR¹⁴CO₂, NR¹⁵SO₂, NR¹⁶SO₂NR¹⁷, SO₂NR¹⁸, CONR¹⁹, halogen, nitro, cyano, or X or Y are absent;

15 R1 is hydrogen, CH₃, OH, OCH₃, SH, SCH₃, OCOR²¹, SOR²², SO₂R²³, SO₂NR²⁴R²⁵, CO₂R²⁶, CONR²⁷R²⁸, NH₂, NR²⁹SO₂NR³⁰R³¹, NR³²SO₂R³³, NR³⁴COR³⁵, NR³⁶CO₂R³⁷, NR³⁸CONR³⁹R⁴⁰, halogen, nitro, or cyano;

R² and R³ are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenyl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heterocycloalkyl or substituted heterocycloalkyl, or when X is halo, nitro or cyano R² is absent or when Y is halo, nitro or cyano R³ is absent;

R⁶ is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, NR⁷R⁸, OR⁹ or halogen;

25 R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²¹, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁸, R²⁸, R³⁰, R³¹, R³², R³⁴, R³⁵, R³⁶, R³⁸, R³⁹ and R⁴⁰ are independently selected

15

from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo;

R²³, R²³, R³³ and R³⁷ are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo; and

$$R^{42}$$
 is $(R^{43})_n$

wherein

10 each R⁴³ is independently selected from fluorine or methyl;

n is 0, 1 or 2; and

R⁴⁴ is methyl, ethyl or cyclopropylmethyl;

with the further provisos that:

- a. R² may not be hydrogen if X is SO, SO₂, NR¹³CO₂, or NR¹⁴SO₂, and
- b. R³ may not be hydrogen if Y is SO, SO₂, NR¹³CO₂, or NR¹⁴SO₂.
- 2. The compound of formula (I) according to Claim 1, selected from the group consisting of:
- 5-(1-Methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one-6-carboxylic acid 20 ethyl ester.
 - $\label{lem:condition} \mbox{4-Chloro-} [2,1-f] [1,2,4] \mbox{triazin-} 5-(1-\mbox{Methylethyl}) \mbox{pyrrolo-} 6-\mbox{carboxylic acid ethyle ester,} \\ \mbox{ester},$
 - $\label{eq:condition} 4-Chloro-5-(1-methylethyl)-6-(5-methyl-2-oxazolyl) pyrrolo[2,1-f][1,2,4] triazin,$
- 25 4-[[3-[(Methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,

10

15

20

25

30

```
4-[[2-Fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-fl[1,2,4]triazine-6-carboxylic acid ethyl ester,
       4-[[2-Fluoro-5-[(methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,
       4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,
       4-[[4-Fluoro-3-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,
       4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester,
       4-[3-[(Methoxyamino)carbonyl]phenoxy]-5-(1-methylethyl)pyrrolo[2,1-
f][1,2,4]triazine-6-carboxylic acid, ethyl ester,
       4-[2-Fluoro-3-[(methoxyamino)carbonyl]phenoxy]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, ethyl ester,
       4-[[2-Fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid,
       N-Ethyl-4-[[2-fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
       N-[2-(Dimethylamino)ethyl]-4-[[2-fluoro-5-[(methoxyamino)carbonyl]
phenyllamino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
       4-[[2-Fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-N-(2-hydroxyethyl)-
5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
       4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-N-methyl-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
       4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-methylethyl)-
N-[2-(1-pyrrolidinyl)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
       [4-[[3-[(Methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-
methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-methyl-2-
pyrrolidinyl)ethyl ester,
```

4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(methylsulfonyl)propyl ester.

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-

5 methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(1-piperidinyl)propyl ester,

5-[[6-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

5-[[6-Ethoxy-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-fluoro-N-methoxy-2-methylbenzamide,

5-[[6-Acetyl-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-N-methoxy-2-methylbenzamide,

 2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(2-methyl-1H-1,2,4-triazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(1-methyl-1H-1,2,4-triazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-[5-

20 [(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

 $\label{eq:continuity} 5-[[6-[5-[Difluoro(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,$

25 5-[[6-[5-(Dimethylamino)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-methyl-1H-1,2,4-triazol-5-yl)ethyl ester,

30 [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (1-methyl-4-piperidinyl)methyl,

10

15

20

25

30

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, 3-(1H-1,2,3-triazol-1-yl)propyl ester.

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, 2-(1H-1,2,3-triazol-1-yl)ethyl ester.

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, 3-(6-methyl-2-pyridinyl) propyl ester

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(methylsulfonyl)ethyl ester,

[4-[[2,4-Difluoro-5-((methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (2-butyl-1H-imidazol-4-yl)methyl ester,

 $[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][[1,2,4]triazin-6-yl]carbamic acid 2-(4-pyridinyl)ethyl ester, \\ [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methoxyamino)carbonyl]phenyl]amino]-5-(1-methoxyamino)carbonyl]phenyl]amino]-5-(1-methoxyamino)carbonyl]phenyl]amino]-5-(1-methoxyamino)carbonyl]phenyl]amino]-5-(1-methoxyamino)carbonyl]phenyl]amino]-5-(1-methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)carbonyll[amino]-5-(1-methylethyl)carbonyll[amino]-5-(1-methylethyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[amino]-5-(1-methyll)carbonyll[$

methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-

(dimethoxyphosphinyl)ethyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (6-methyl-2-pyridinyl)methyl ester.

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid [(2S)-1-methyl-2-pyrrolidinyl]methyl ester.

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid (1-methyl-2-piperidinyl)methyl ester,

[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 1-methyl-4-piperidinyl ester.

```
[4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 4-pyridinylmethyl ester,
             [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-pyridinylmethyl ester,
 5
             [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-fl[1,2,4]triazin-6-yl]carbamic acid 2-(2-pyridinyl)ethyl ester,
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-pyridinylmethyl ester,
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
10
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(4-morpholinyl)ethyl
      ester.
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-methyl-2-
      pyrrolidnyl)ethyl ester,
15
             [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 1-methyl-3-pyrrolidnyl
      ester,
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-ethoxyethyl ester,
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
20
      methylethyl)pyrrolo[2.1-f][1,2.4]triazin-6-yl]carbamic acid [5-
      [(dimethylamino)methyl]-2-furanyl]methyl ester,
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 2-(1-piperidinyl)ethyl
25
      ester.
             [4-[[2.4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
      methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-hydroxybutyl ester,
             4-Fluoro-N-methoxy-3-[[5-(1-methylethyl)-6-(5-methyl-2-
      oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,
```

2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-

oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,

2-Fluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yllamino]benzamide.

N-Methoxy-2-methyl-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2.1-f][1.2.4]triazin-4-yllamino]benzamide.

- 5 4-Fluoro-N-methoxy-2-methyl-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,
 - 2-Chloro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,
- $\label{eq:condition} 2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-1,2,4-oxadiazol-10 3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,$

and pharmaceutically acceptable salts and prodrugs thereof.

- 3. A compound selected from the group consisting of
- [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-
- 15 methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(methylsulfonyl)propyl ester,
 - [4-[[2,4-Difluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid 3-(1-piperidinyl)propyl ester.
- 5-[[6-[5-(Difluoromethyl)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,
 - 2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(2-methyl-1H-1,2,4-triazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide,
 - 2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-[5-
- 25 [(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]aminolbenzamide.
 - $\label{eq:continuous} 5-[[6-[5-[Difluoro(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,$
- 30 5-[[6-[5-(Dimethylamino)-1,3,4-oxadiazol-2-yl]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-2,4-difluoro-N-methoxybenzamide,

10

- 4-Fluoro-N-methoxy-3-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2,4]triazin-4-yllamino]benzamide,
- 2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-2-oxazolyl)pyrrolo[2,1-f][1,2.4]triazin-4-yllamino]benzamide, and
- 2,4-Difluoro-N-methoxy-5-[[5-(1-methylethyl)-6-(5-methyl-1,2,4-oxadiazol-3-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzamide.
- A pharmaceutical composition comprising at least one of the compounds of Claim 1 and a pharmaceutically acceptable carrier.
- A pharmaceutical composition comprising at least one of the compounds of Claim I in combination with pharmaceutically acceptable carrier and an anticancer or cytotoxic agent.
- 15 The pharmaceutical composition as recited in Claim 5, wherein said anticancer or cytotoxic agent is selected from the group consisting of: linomide, inhibitors of integrin $\alpha v \beta 3$ function, angiostatin, razoxane, tamoxifen, toremifene, raloxifene. droloxifene, iodoxifene, megestrol acetate, anastrozole, letrozole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, gosereline 20 acetate, leuprolide, finasteride, herceptin, metalloproteinase inhibitors, inhibitors of urokinase plasminogen activator receptor function, growth factor antibodies, growth factor receptor antibodies, bevacizumab, cetuximab, tyrosine kinase inhibitors, serine/threonine kinase inhibitors, methotrexate, 5-fluorouracil, purine, adenosine analogues, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, 25 mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa, vincristine, paclitaxel, docetaxel, epothilone analogs, discodermolide analogs, eleutherobin analogs, etoposide, teniposide, amsacrine, topotecan, irinotecan, flavopyridols, proteasome inhibitors including bortezomib and biological response 30 modifiers.

- 7. A method for producing an antiangiogenic effect which comprises administering to a mammalian species in need thereof, an effective antiangiogenic producing amount of at least one of the compounds of Claim 1.
- 8. A method for producing a vascular permeability reducing effect which comprises administering to a mammalian species in need thereof an effective vascular permeability reducing amount of at least one of the compounds of Claim 1.
- A method of inhibiting protein kinase activity of growth factor receptors
 which comprises administering to a mammalian species in need thereof, an effective protein kinase inhibiting amount of at least one of the compounds of Claim 1.
 - 10. A method of inhibiting tyrosine kinase activity of growth factor receptors which comprises administering to a mammalian species in need thereof, an effective tyrosine kinase inhibiting amount of at least one of the compounds of Claim 1.
- A method for treating proliferative diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a
 composition of Claim 4.
 - A method for treating cancer, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim

15

- 13. A method for treating inflammation, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 4.
- 30 14. A method for treating autoimmune diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 4.

15. A method for treating proliferative diseases, comprising administering to mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.

5

25

- 16. A method for treating cancer, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.
- 10 17. A method for treating inflammation, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.
- 18. A method for treating autoimmune diseases, comprising administering to a mammalian species in need thereof, a therapeutically effective amount of a composition of Claim 5.
- 19. A method for treating diseases associated with signal transduction pathways operating through growth factor receptors, which comprises administering
 to a mammalian species in need thereof a therapeutically effective amount of at least one of the compounds of Claim 1.
 - 20. A compound selected from
 - 3-Amino-4-fluoro-N-methoxybenzamide,
 - 5-amino-2-methyl-4-fluoro-N-methoxybenzamide,
 - 5-amino-2-methyl-N-methoxycarboxamide, or
 - 5-amino-2,4-difluoro-N-methoxybenzamide.